Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.42 USD
Change Today +0.11 / 0.47%
Volume 375.0K
SGNT On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Jeffrey M. Yordon

Founder and Director, Sagent Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 13 board members in 3 different organizations across 4 different industries.

See Board Relationships
65$1,914,167
As of Fiscal Year 2014

Background*

Mr. Jeffrey M. Yordon Founded Sagent Pharmaceuticals, Inc. in 2006 and served as its Chairman and Chief Executive Officer since April 2006 until March 2015. Mr. Yordon served as the President of Sagent Pharmaceuticals from April 2006 to March 25, 2013. He has more than 35 years of injectables experience. He served as the Chairman, President and Chief Strategic Officer of Fresenius Kabi Pharmaceuticals Holding, Inc. He served as a Co-Chief Operating Officer of Fresenius ...

Read Full Background

Corporate Headquarters*

1901 North Roselle Road
Schaumburg, Illinois 60195

United States

Phone: 847-908-1600
Fax: 847-908-1601

Board Members Memberships*

Founder and Director
1997-2005
Former Co-Chief Operating Officer and Director

Education*

BSBA
Northern Illinois University

Other Affiliations*

Annual Compensation*

Salary$645,810
Total Annual Compensation$645,810

Stock Options*

Restricted Stock Awards$270,003
All Other Compensation$21,785
Exercisable Options512,970
Exercisable Options Value$5,615,545
Unexercisable Options102,879
Unexercisable Options Value$1,090,991
Total Value of Options$7,814,035
Total Number of Options865,849

Total Compensation*

Total Annual Cash Compensation$1,365,070
Total Short Term Compensation$645,810
Other Long Term Compensation$291,788
Total Calculated Compensation$1,914,167
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $23.42 USD +0.11

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Friedhelm Blobel Ph.D.Chief Executive Officer, President, Executive Director and Member of Business Development Committee
SciClone Pharmaceuticals, Inc.
$566.5K
Douglas A. Michels Chief Executive Officer, President and Director
OraSure Technologies, Inc.
$580.1K
Yongfeng Zhang Ph.D.Chief Executive Officer, Chief Science Officer and Director
Amphastar Pharmaceuticals, Inc.
$1.4M
Aijaz Tobaccowalla Managing Director, Director, Member of Nomination and Remuneration Committee and Member of Board Administrative Committee
Pfizer Limited
30.3M
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
$440.2K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.